These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19228734)

  • 1. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
    Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
    Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
    Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
    Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
    Hawthorne VS; Huang WC; Neal CL; Tseng LM; Hung MC; Yu D
    Mol Cancer Res; 2009 Apr; 7(4):592-600. PubMed ID: 19372587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
    Ling X; Bernacki RJ; Brattain MG; Li F
    J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells.
    Zhu H; Zhang G; Wang Y; Xu N; He S; Zhang W; Chen M; Liu M; Quan L; Bai J; Xu N
    Cancer Sci; 2010 May; 101(5):1156-62. PubMed ID: 20331626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
    Chen J; Ren Q; Cai Y; Lin T; Zuo W; Wang J; Lin R; Zhu L; Wang P; Dong H; Zhao H; Huang L; Fu Y; Yang S; Tan J; Lan X; Wang S
    Biochem Biophys Res Commun; 2018 Jun; 501(1):212-219. PubMed ID: 29715459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.
    Tan M; Jing T; Lan KH; Neal CL; Li P; Lee S; Fang D; Nagata Y; Liu J; Arlinghaus R; Hung MC; Yu D
    Mol Cell; 2002 May; 9(5):993-1004. PubMed ID: 12049736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
    Yu D; Jing T; Liu B; Yao J; Tan M; McDonnell TJ; Hung MC
    Mol Cell; 1998 Nov; 2(5):581-91. PubMed ID: 9844631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways.
    Siddiqa A; Long LM; Li L; Marciniak RA; Kazhdan I
    BMC Cancer; 2008 May; 8():129. PubMed ID: 18454859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.